Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$2.78
+1.1%
$3.02
$1.30
$4.08
$729.15M0.683.02 million shs2.40 million shs
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$24.14
-3.9%
$25.37
$16.10
$35.72
$3.17B0.692.39 million shs1.54 million shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$22.47
+0.7%
$19.90
$9.60
$24.57
$2.99B1.571.08 million shs939,181 shs
Indivior PLC stock logo
INDV
Indivior
$23.87
+0.4%
$23.56
$7.33
$25.10
N/A0.72.11 million shs884,981 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-2.83%-6.78%-30.73%+108.33%
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%+5.68%+1.22%+26.33%-7.32%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%-3.96%+2.29%+47.46%+39.52%
Indivior PLC stock logo
INDV
Indivior
0.00%+2.63%+2.46%+52.24%+218.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$2.78
+1.1%
$3.02
$1.30
$4.08
$729.15M0.683.02 million shs2.40 million shs
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$24.14
-3.9%
$25.37
$16.10
$35.72
$3.17B0.692.39 million shs1.54 million shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$22.47
+0.7%
$19.90
$9.60
$24.57
$2.99B1.571.08 million shs939,181 shs
Indivior PLC stock logo
INDV
Indivior
$23.87
+0.4%
$23.56
$7.33
$25.10
N/A0.72.11 million shs884,981 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-2.83%-6.78%-30.73%+108.33%
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%+5.68%+1.22%+26.33%-7.32%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%-3.96%+2.29%+47.46%+39.52%
Indivior PLC stock logo
INDV
Indivior
0.00%+2.63%+2.46%+52.24%+218.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.71
Moderate Buy$6.75142.81% Upside
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.45
Hold$33.2937.92% Upside
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.91
Moderate Buy$32.3844.08% Upside
Indivior PLC stock logo
INDV
Indivior
2.88
Moderate Buy$22.00-7.83% Downside

Current Analyst Ratings Breakdown

Latest AKBA, INDV, CNTA, and APLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Indivior PLC stock logo
INDV
Indivior
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/6/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$28.00
10/3/2025
Indivior PLC stock logo
INDV
Indivior
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/27/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Indivior PLC stock logo
INDV
Indivior
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
9/26/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutralSell$26.00 ➝ $18.00
(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$160.18M4.60N/AN/A($0.23) per share-12.09
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M3.90N/AN/A$1.84 per share13.12
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$6.85M439.26N/AN/A$3.05 per share7.37
Indivior PLC stock logo
INDV
Indivior
$1.19BN/A$1.83 per share13.06($2.52) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$2M$0.6238.5013.96N/A6.65%-86.28%16.26%10/23/2025 (Estimated)

Latest AKBA, INDV, CNTA, and APLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.02N/AN/AN/A$52.06 millionN/A
11/4/2025Q3 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$0.73N/AN/AN/A$364.58 millionN/A
10/23/2025Q3 2025
Indivior PLC stock logo
INDV
Indivior
$0.38N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A
7/31/2025Q2 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 million
7/31/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.26$0.51+$0.25$0.14$239.43 million$302.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.61
1.98
1.84
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.90
3.77
3.16
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.32
10.11
10.12
Indivior PLC stock logo
INDV
Indivior
N/A
0.90
0.76

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
Indivior PLC stock logo
INDV
Indivior
60.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430265.14 million257.19 millionOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770126.29 million117.70 millionOptionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200133.91 million124.42 millionOptionable
Indivior PLC stock logo
INDV
Indivior
1,051N/AN/ANot Optionable

Recent News About These Companies

12 Best Performing Healthcare Stocks to Buy Right Now
Indivior Updates CFO Employment Agreements
Indivior to Participate in Upcoming Investor Events
The Street Loves This ‘Strong Buy’ Pharma Stock
Indivior Raises 2025 Guidance After Strong Q2 Results
Indivior (INDV) Q2 EPS Jumps 104%
Best Momentum Stock to Buy for August 5th
New Strong Buy Stocks for August 5th
Indivior (INDV) Extends Jump on 3rd Day with 16% Gain
10 Stocks Crushing With Whopping Double-Digit Gains

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$2.78 +0.03 (+1.09%)
Closing price 04:00 PM Eastern
Extended Trading
$2.80 +0.02 (+0.72%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$24.14 -0.98 (-3.90%)
Closing price 04:00 PM Eastern
Extended Trading
$23.97 -0.17 (-0.71%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$22.47 +0.16 (+0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$22.46 0.00 (-0.02%)
As of 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Indivior stock logo

Indivior NASDAQ:INDV

$23.87 +0.09 (+0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$23.52 -0.35 (-1.45%)
As of 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.